Will Pralsetinib be included in medical insurance in 2023?

Pralsetinib (Pralsetinib) is a once-daily oral targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer detected by an FDA-approved test. It is designed to selectively and efficiently target oncogenic RET alterations. In preclinical studies, platinib inhibited RET at lower concentrations than other pharmacologically relevant kinases, including VEGFR2, FGFR2, and JAK2.

Platinib is not approved by the FDA for the treatment of any other indications in the United States. Blueprint Medicines and Roche are jointly developing platinib globally for the treatment of RET-mutated MTC and RET fusion-positive thyroid cancer. Platinib will be available in a dose strength of 100 mg, with a recommended starting dose of 400 mg once daily.

It is understood that the original drug Platinib has been marketed in China, but it has not yet entered the scope of medical insurance through the relevant regulations of the National Medical Insurance Bureau. Patients in need can only purchase it at their own expense. The price of each box of 100mg*120 tablets may be around RMB 60,000, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.